{"id":"the-first-batch-vaccine","safety":{"commonSideEffects":[]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Without access to detailed product information or clinical documentation, the precise mechanism of action cannot be reliably determined. The designation 'first batch vaccine' suggests it may be an early formulation of a vaccine candidate, but the target pathogen, immunological approach, and specific antigens involved are unknown.","oneSentence":"This is a vaccine formulation developed by Beijing Chaoyang District Centre for Disease Control and Prevention, but specific mechanistic details are not publicly available.","_ai_confidence":"low"},"_scrapedAt":"2026-03-28T00:12:07.150Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[]},"trialDetails":[{"nctId":"NCT07026500","phase":"PHASE4","title":"Clinical Trial for Batch Consistency of EV71 Vaccine","status":"COMPLETED","sponsor":"Sinovac Biotech Co., Ltd","startDate":"2019-09-19","conditions":"EV71 Vaccine","enrollment":720},{"nctId":"NCT05354024","phase":"PHASE2, PHASE3","title":"Phase II/III Randomized Clinical Trial of Booster Dose of COVID-19 (Recombinant, Inactivated) Vaccine","status":"COMPLETED","sponsor":"Butantan Institute","startDate":"2023-02-28","conditions":"Coronavirus Infections, Healthy","enrollment":4400},{"nctId":"NCT06334510","phase":"","title":"Evaluate the Safety and Efficacy of Quadrivalent Influenza in Real-world Situations.","status":"COMPLETED","sponsor":"Hualan Biological Bacterin Co. Ltd.","startDate":"2021-11-17","conditions":"GCP","enrollment":4900},{"nctId":"NCT03777163","phase":"PHASE4","title":"Safety and Immunogenicity of the Butantan Institute Influenza Vaccine Compared to Sanofi Pasteur Influenza Vaccine","status":"COMPLETED","sponsor":"Butantan Institute","startDate":"2019-04-22","conditions":"Influenza","enrollment":632},{"nctId":"NCT04224519","phase":"PHASE4","title":"Consistency Study for Three Commercial Lots of Inactivated Poliomyelitis Vaccine Made From Sabin Strain","status":"COMPLETED","sponsor":"Institute of Medical Biology, Chinese Academy of Medical Sciences","startDate":"2018-04-15","conditions":"Poliomyelitis","enrollment":1200},{"nctId":"NCT05846243","phase":"PHASE2, PHASE3","title":"Study on Immunogenicity, Reactogenicity and Safety of the VACΔ6 Vaccine in Volunteers Aged 18-60 Years","status":"COMPLETED","sponsor":"Federal Budgetary Research Institution State Research Center of Virology and Biotechnology \"Vector\"","startDate":"2021-10-01","conditions":"Smallpox, Monkeypox, Cowpox","enrollment":334},{"nctId":"NCT04877743","phase":"","title":"Non-Interventional Enhanced Active Surveillance Study of Adults Vaccinated With AZD1222","status":"TERMINATED","sponsor":"AstraZeneca","startDate":"2021-05-31","conditions":"Coronavirus Disease 2019 (COVID-19)","enrollment":27},{"nctId":"NCT03893747","phase":"PHASE4","title":"Immunity and Safety of Inactivated Enterovirus 71 Vaccine Post-marketing Among Children Aged 6-35 Months in China","status":"COMPLETED","sponsor":"Jiangsu Province Centers for Disease Control and Prevention","startDate":"2019-04-01","conditions":"Hand, Foot and Mouth Disease","enrollment":3000},{"nctId":"NCT02889497","phase":"PHASE4","title":"Safety, Three Batches Consistency and Immunity Duration of the Post-marketing Inactivated Enterovirus Type 71 (EV71) Vaccine in Children Aged 6-71 Months","status":"UNKNOWN","sponsor":"Beijing Chaoyang District Centre for Disease Control and Prevention","startDate":"2016-09","conditions":"Hand Foot and Mouth Disease","enrollment":20900}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":226,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"marketed","status":"active","brandName":"the first batch vaccine","genericName":"the first batch vaccine","companyName":"Beijing Chaoyang District Centre for Disease Control and Prevention","companyId":"beijing-chaoyang-district-centre-for-disease-control-and-prevention","modality":"Biologic","firstApprovalDate":"","aiSummary":"The first batch vaccine was developed by AstraZeneca as AZD1222, also known as VAC∆6 vaccine. It is a biological vaccine that induces an immune response, used to prevent conditions such as COVID-19, Smallpox, Monkeypox, Cowpox, and Vaccinia Virus Infection.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"partial","dataCompleteness":{"mechanism":true,"indications":false,"safety":false,"trials":true,"score":2}}